Business Context and Reporting Period
Company: Silexion Therapeutics Corp (formerly Biomotion Sciences)
Reporting Date: August 21, 2024 (Event Date: August 15, 2024)
Event: Consummation of a Business Combination with Moringa Acquisition Corp (SPAC) and Silexion Therapeutics Ltd. The registrant changed its name from "Biomotion Sciences" to "Silexion Therapeutics Corp" and ceased to be a shell company.
Trading Symbols: Ordinary Shares (SLXN) and Warrants (SLXNW) commenced trading on the Nasdaq Global Market on August 16, 2024.
Key Financial Metrics and Capital Structure
Share Capital: Immediately following the Closing, 9,768,396 New Silexion ordinary shares were issued and outstanding.
Redemptions: 427,297 Moringa public shares were redeemed for approximately $11.575 per share, totaling $4,946,046.
Trust Account Balance: After redemptions and fees, the remaining balance of $333,936 was used to partially fund the Business Combination.
Debt and Obligations:
- EarlyBird Convertible Note: $1.25 million issued to EarlyBird Capital, Inc. (plus $350,000 cash paid from Trust). Interest rate is 6% per annum (increases to 15% upon default). Matures December 31, 2025. Mandatory prepayments required from 10% of gross proceeds from future equity financings.
- Sponsor Promissory Note: $3,433,000 amended and restated note owed to the Sponsor. Matures February 15, 2027. Repayable primarily via conversion into ordinary shares.
Equity Financing:
- PIPE Financing: Raised $2.0 million via the sale of 200,000 shares to Greenstar, LP at $10.00 per share.
- Equity Line of Credit (ELOC): Entered into an agreement with White Lion Capital, LLC for up to $15.0 million in share sales through December 31, 2025.
Revenue and Profit: The filing text does not provide specific revenue or profit figures for the combined entity in this 8-K. The company is a development-stage entity and has never generated revenue from product sales.
Material Changes Versus Prior Period
- Corporate Status: Transitioned from a SPAC shell company (Biomotion Sciences) to an operating biopharmaceutical company (Silexion Therapeutics Corp).
- Ownership Structure: Significant dilution and restructuring occurred. 427,297 shares were redeemed, while 4,024,942 shares were issued as merger consideration to Silexion securityholders. Additional shares were issued for the PIPE, Sponsor investment, and Chinese subsidiary transfer.
- Debt Profile: New debt obligations were created, specifically the $1.25 million EarlyBird Convertible Note and the $3.433 million Sponsor Promissory Note, replacing prior SPAC obligations.
- Subsidiary Structure: Silexion Therapeutics Ltd. and Moringa Acquisition Corp became wholly-owned subsidiaries. The Chinese subsidiary, Silenseed (China) Ltd., became a wholly-owned subsidiary following the transfer of noncontrolling interest.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: The company focuses on discovering and developing novel RNAi therapeutics for oncology. Management anticipates the need to raise substantial additional funding, which may not be available on acceptable terms.
Risks and Contingencies:
- Liquidity Risk: The company has no revenue and requires significant capital for clinical development. Failure to raise funds could lead to bankruptcy or liquidation.
- Debt Repayment Risk: The EarlyBird Convertible Note requires mandatory prepayments from future equity financing proceeds. If not converted or repaid by maturity, the interest rate increases to 15%, and the note may become immediately due.
- Dilution Risk: Significant potential dilution exists from the conversion of the EarlyBird Note, the Sponsor Promissory Note, the ELOC (up to $15M), and outstanding warrants.
- Development Risk: The approach to RNAi therapeutics is unproven for oncology, and the company has no experience producing products at commercial levels.
Unusual Items: The transaction involved a complex series of mergers, share conversions, and the acceleration of vesting for certain options and RSUs immediately prior to the Acquisition Merger.
Important Facts for Investor Verification
- Cash Position: Verify the exact cash balance available post-closing, as the Trust Account was largely depleted by redemptions ($4.9M) and fees, leaving only $333,936 plus the $2.0M PIPE proceeds.
- Debt Covenants: Review the mandatory prepayment terms of the EarlyBird Convertible Note, which could restrict future fundraising flexibility.
- Dilution Potential: Assess the total potential share count increase from the ELOC ($15M), convertible notes ($4.683M total principal), and outstanding warrants.
- Lock-Up Periods: Note that 50% of Sponsor Investment Shares and former Silexion shareholder securities are locked up for 6 months or until the stock price exceeds $12.00 for 20 trading days within a 30-day period.
- Financial Statements: Refer to Exhibit 99.1 for unaudited condensed consolidated financial statements of Silexion as of June 30, 2024, and Exhibit 99.2 for pro forma combined financial information.